Abstract: An induction method for a macrophage is provided, in which macrophages are cultured in the presence of exosomes produced from a mesenchymal stem cell to which interferon gamma has been added and are induced into anti-inflammatory macrophages. An anti-inflammatory macrophage-inducing agent includes exosomes produced from a mesenchymal stem cell to which interferon gamma has been added, as an active component. A pharmaceutical composition contains the inducing agent.
Abstract: Embodiments for a portable and compact centrifugation and thermal management system capable of separating and transporting biological samples while maintaining sample quality for periods of shipment time are described. A compact, automatic centrifuge holding exactly one sample tube is inside an insulating and thermally managed container suitable for standard shipping. A rotor to retain a sample tube is pre-balanced. An electronic controller starts, times and stops centrifugation automatically, responsive to placement of a lid. Thermal management may comprise a phase change material. Embodiments are free of user controls. Embodiments are free of the need for external power or external control.
Type:
Grant
Filed:
July 26, 2021
Date of Patent:
July 1, 2025
Assignee:
LABORATORY CORPORATION OF AMERICA HOLDINGS
Inventors:
Ulrich Schaff, Angela Le, Tifany Pan, Kyungjin Hong, Clara Neal
Abstract: Disclosed is a stem cell generator for the generation of organoids after the development of biological materials loaded with active substances which are implanted into an animal or a human body. The active substances are mesenchymal stem cells, bone morphogenetic protein-2 or bone morphogenesis protein-7, other growth factors/polypeptides or growth factors/polypeptide combinations having the ability of inducing bone regeneration, or combinations thereof. The stem cell generator contains various types of blood cells and hematopoietic progenitor/stem cells having complete functions. The produced stem cells are used for treating hematopoietic damage, and can treat bone marrow failure and leukemia caused by radiotherapy/chemotherapy.
Type:
Grant
Filed:
January 21, 2020
Date of Patent:
July 1, 2025
Assignee:
EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY
Inventors:
Changsheng Liu, Kai Dai, Jing Wang, Guilong Li, Qinghao Zhang, Shunshu Deng
Abstract: The present invention comprises methods and composition for control of plant pathogens. Isolated bacteria, deposited with ATCC under the Budapest Treaty, are effective to control plant pathogens.
Abstract: U biosensors, and related U-sensing genetic molecular components, genetic circuits, compositions, methods and systems are described, which in several embodiments can be used to detect and/or neutralize uraniunm and in particular bioavailable U.
Type:
Grant
Filed:
March 17, 2023
Date of Patent:
May 13, 2025
Assignee:
LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
Abstract: Disclosed are techniques and systems for producing microbials having anaplerotic oils that are rich in odd-chain fatty acids, and other beneficial components, at higher concentrations than those present in other natural dietary sources of OCFA, at lower cost, and higher production yield. Further, disclosed are examples of incorporation of these higher concentration OCFA products into food for human and non-human animal consumption.
Abstract: A method for promoting weight management in a mammal is provided, comprising administering to the mammal a weight loss agent and a mitochondria enhancing agent. Compositions for weight management are also provided.
Abstract: A taste and flavor profile modifying composition is described. The composition includes a blend of glucosylated steviol glycosides and residual steviol glycosides which can modify the intensity of a taste and/or flavor in a food or beverage product.
Abstract: The present disclosure relates to liquid (e.g., water-soluble) compositions comprising antimethanogenic compounds, and methods of administering the same to reduce enteric methane emissions from ruminant animals, and/or improve feed-efficiency. Certain disclosed compositions exhibit improved rapid effect over prior art compositions. The disclosure further relates to methods of concentrating antimethanogenic compounds, extracting antimethanogenic compounds, and methods of increasing the bioavailability of antimethanogenic compounds.
Abstract: A method for preparing an autologous pancreatic tumor organoid and immune cell co-culture is provided, including: culturing pancreatic tumor cells obtained from a patient in a culture medium to provide a pancreatic tumor organoid and an organoid-conditioned medium; pulsing dendritic cells derived from the patient with a portion of the organoid-conditioned medium; contacting the pulsed dendritic cells with cytotoxic T lymphocytes (CTLs) obtained from the patient in the organoid-conditioned medium to activate the CTLs; isolating the activated CTLs; and co-culturing the pancreatic tumor organoid with the activated CTLs and myeloid derived suppressor cells (MDSCs) derived from the patient, to obtain an autologous pancreatic tumor organoid and immune cell co-culture that mimics the patient's pancreatic tumor microenvironment. Also provided are co-cultures obtained by the disclosed methods and methods of screening and determining whether a patient is likely to benefit from a candidate therapy.
Abstract: An object of the present invention is to provide a novel method for producing a biological tissue-like structure comprising differentiated cells induced from pluripotent stem cells, and the present invention provides a method of forming a biological tissue-like structure together with host-derived blood vessels and connective tissue by transplanting a composition in which cells derived from pluripotent stem cells are disposed to be dispersed in a biocompatible material to induce the differentiation of the cells.
Abstract: Methods are disclosed herein for producing a mammalian acoustic extracellular matrix (ECM) hydrogel. In further embodiments, mammalian acoustic ECM hydrogels are disclosed that are produced using the disclosed methods. Also disclosed is a mammalian acoustic ECM hydrogel, wherein the hydrogel is thermoreversible. Methods of using these acoustic ECM hydrogels are also disclosed.
Type:
Grant
Filed:
March 12, 2020
Date of Patent:
April 1, 2025
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Inventors:
Stephen Francis Badylak, George S. Hussey
Abstract: The apparatuses described herein relate to preparation of a meat product. Apparatuses, systems comprising the apparatuses, and methods of making and use the systems and apparatuses are described herein. These are useful for controlling one or more of growth on and separation of a meat product from an enclosed substrate. The apparatuses and systems are configured to receive fluid and grow the meat product and/or separate the meat product from the substrate in a scalable manner.
Type:
Grant
Filed:
February 12, 2024
Date of Patent:
March 25, 2025
Assignee:
Upside Foods, Inc.
Inventors:
Matthew Leung, Michelle Warner, Ryan Edward Vanderpol, Thomas Pei-Ja Hsiu, Kathleen Carswell
Abstract: The invention provides compositions comprising chitosan, manuka honey and one or more additional components that promotes digestive health (e.g., inulin, probiotics) for the treatment and prevention of gastric ulcers (esophageal, stomach, or duodenum) in a mammal (e.g., equine).
Type:
Grant
Filed:
June 20, 2023
Date of Patent:
March 18, 2025
Assignee:
SIDR, LLC
Inventors:
Scott P. Noel, William Brian Austin, Alex Greene, John Kirk Shumpert
Abstract: Long awaited is a human liver-like three-dimensional construct that makes it possible to carry out evaluation of human-specific toxicity and the like accurately and in a simple manner. The present invention provides a human liver-like three-dimensional construct comprising a heterospheroid, in which human hepatic cells and other human-derived cells which are not human hepatic cells are aggregated. This human liver-like three-dimensional construct is characterized in that the other human-derived cells are at least one selected from human hepatic stellate cells and the like, and the other human-derived cell to the human hepatic cell count ratio is at least 0.01 but less than 1.
Type:
Grant
Filed:
February 21, 2020
Date of Patent:
March 11, 2025
Assignee:
CYFUSE BIOMEDICAL K.K.
Inventors:
Toshihiko Maekawa, Eri Nagao, Izumi Ide, Sakura Kajiyama
Abstract: The present invention relates to compositions and methods for mass production of pluripotent stem cells derived from non-human-animal, particularly in a form of aggregates suitable for a variety of uses, particularly to mass production of aggregates of bovine-derived pluripotent stem cells for use in cell grown meat cultures and in production of cell based meat products.
Type:
Grant
Filed:
May 14, 2020
Date of Patent:
March 11, 2025
Assignee:
ALEPH FARMS LTD.
Inventors:
Neta Lavon, Didier Toubia, Anna Bodanovsky
Abstract: The present invention relates to a pharmaceutical composition including vitrified periodontal tissue-derived mesenchymal stem cells for prevention or treatment of male infertility. The pharmaceutical composition for prevention or treatment of male infertility according to the present invention recovers sex hormone levels in seminiferous tubules of atrophic testes and blood to normal levels through improvement in the activity of lipid metabolism enzymes in the liver, thereby exhibiting remarkable prophylactic and therapeutic effects on male infertility. In addition, the periodontal tissue-derived mesenchymal stem cells which are an active ingredient in the present invention can be obtained in the most non-invasive manner and as such, are expected to be advantageously used as a cell therapy product for male infertility.
Type:
Grant
Filed:
May 8, 2020
Date of Patent:
March 4, 2025
Assignees:
Industry-Academic Cooperation Foundation Gyeongsang National University, Stemcentric Co., Ltd.
Inventors:
Gyu Jin Rho, Kyung Min Kim, Si Jung Jang, Sung Lim Lee, Bong Wook Park
Abstract: A composition for improving respiratory health of companion animals, includes butyric acid as a short-chain fatty acid, propionic acid as a short-chain fatty acid, acetic acid as a short-chain fatty acid, red ginseng extract powder, Siberian gooseberry extract powder, omega-3 fatty acid, glutathione powder, chlorella powder, spirulina powder, propolis powder, plantago seed (psyllium) husk powder, zinc powder and CTF-901 as active ingredients, thereby inhibiting bronchial thickening in airway smooth muscle cells through edible feeding thus to contribute to enhancement of respiratory health.
Abstract: Provided are a culture medium for expanding and cultivating human liver progenitor cells and an application thereof. The chemical components of the formula of the described culture medium are clear, no serum is present, and various components thereof cooperate with each other to synergize. The culture medium is used for the long-term expansion and cultivation of liver progenitor cells in vitro and is used for maintaining the dryness thereof, is beneficial in quickly and efficiently obtaining a large number of functional liver cells, and is suitable for clinical hepatocyte transplantation application as well as for the use of hepatocyte reactors in bioartificial livers.
Type:
Grant
Filed:
December 19, 2019
Date of Patent:
February 25, 2025
Assignee:
GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES
Inventors:
Yinxiong Li, Tingcai Pan, Yan Chen, Yuanqi Zhuang, Fan Yang